两项研究中阿来替尼对经治ALK阳性非小细胞肺癌患者中枢神经系统反应的汇总分析
汇总两项单臂II期研究(NP28761和NP28673),评估阿来替尼600mg每日两次对既往接受克唑替尼治疗的ALK阳性非小细胞肺癌患者中枢神经系统转移的疗效与安全性。136例基线有中枢神经系统转移患者中,可测量中枢神经系统病灶者独立评审委员会评估的中枢神经系统客观缓解率为64.0%,中枢神经系统疾病控制率为90.0%,中位缓解持续时间为10.8个月。阿来替尼对中枢神经系统转移显示出良好疗效,且耐受性良好。
要点
- 基线有可测量中枢神经系统病灶患者的中枢神经系统客观缓解率为64.0%(95%CI 49.2%–77.1%)。
- 基线有可测量和/或不可测量中枢神经系统病灶患者的中枢神经系统客观缓解率为42.6%(95%CI 34.2%–51.4%)。
- 既往接受过中枢神经系统放疗者客观缓解率为35.8%,未接受者为58.5%。
核心结论
- 在克唑替尼难治性ALK阳性非小细胞肺癌患者中,阿来替尼除全身活性外,对中枢神经系统转移显示出良好疗效。
- 阿来替尼耐受性良好,与基线中枢神经系统疾病状态无关。
研究设计与样本
- 汇总两项单臂II期研究(NP28761和NP28673;ClinicalTrials.gov注册号分别为NCT01871805和NCT01801111)的疗效与安全性数据。
- 两项研究均纳入既往接受克唑替尼治疗的ALK阳性非小细胞肺癌患者,所有患者接受阿来替尼600 mg每日两次。
- 两项研究的主要终点均为独立评审委员会(IRC)评估的客观缓解率(ORR;按RECIST版本1.1)。
- 其他终点(均由IRC评估)包括中枢神经系统客观缓解率(CORR)、中枢神经系统疾病控制率(CDCR)和中枢神经系统缓解持续时间(CDOR)。
- 136例患者有基线中枢神经系统转移(占总体研究人群的60%);50例患者(37%)基线有可测量中枢神经系统疾病。
主要发现
- 95例患者(70%)既往接受过中枢神经系统放疗;55例患者在开始阿来替尼前超过6个月完成中枢神经系统放疗。
- 中位随访时间为12.4个月(范围0.9至19.7个月)。
- 基线有可测量中枢神经系统疾病患者中,IRC评估的CORR为64.0%(95%CI 49.2%至77.1%),CDCR为90.0%(95%CI 78.2%至96.7%),中位CDOR为10.8个月(95%CI 7.6至14.1个月)。
- 基线有可测量和/或不可测量中枢神经系统疾病患者中,IRC评估的CORR为42.6%(95%CI 34.2%至51.4%),CDCR为85.3%(95%CI 78.2%至90.8%),中位CDOR为11.1个月(95%CI 10.3个月至不可评估)。
- 既往接受放疗患者(n=95)的CORR为35.8%(95%CI 26.2%至46.3%),未接受放疗患者(n=41)的CORR为58.5%(95%CI 42.1%至73.7%)。
关键数值与推荐
- 基线有可测量中枢神经系统疾病患者:IRC CORR 64.0%(95%CI 49.2%至77.1%),CDCR 90.0%(95%CI 78.2%至96.7%),中位CDOR 10.8个月(95%CI 7.6至14.1个月)。
- 基线有可测量和/或不可测量中枢神经系统疾病患者:IRC CORR 42.6%(95%CI 34.2%至51.4%),CDCR 85.3%(95%CI 78.2%至90.8%),中位CDOR 11.1个月(95%CI 10.3个月至不可评估)。
- 既往接受放疗患者(n=95)CORR 35.8%(95%CI 26.2%至46.3%);未接受放疗患者(n=41)CORR 58.5%(95%CI 42.1%至73.7%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Alectinib has shown activity in the CNS in phase I and II studies. To further evaluate this activity, we pooled efficacy and safety data from two single-arm phase II studies (NP28761 and NP28673; ClinicalTrials.gov identifiers: NCT01871805 and NCT01801111, respectively) in patients with ALK-positive non-small-cell lung cancer (NSCLC). Patients and Methods Both studies included patients with ALK-positive NSCLC who had previously received crizotinib; all patients received alectinib 600 mg twice per day. The primary end point in both studies was independent review committee (IRC)-assessed objective response rate (ORR; by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1). Additional end points (all by IRC) included CNS ORR (CORR), CNS disease control rate (CDCR), and CNS duration of response (CDOR). Results One hundred thirty-six patients had baseline CNS metastases (60% of the overall study populations); 50 patients (37%) had measurable CNS disease at baseline. Ninety-five patients (70%) had prior CNS radiotherapy; 55 patients completed the CNS radiotherapy more than 6 months before starting alectinib. Median follow-up time was 12.4 months (range, 0.9 to 19.7 months). For patients with baseline measurable CNS disease, IRC CORR was 64.0% (95% CI, 49.2% to 77.1%), CDCR was 90.0% (95% CI, 78.2% to 96.7%), and median CDOR was 10.8 months (95% CI, 7.6 to 14.1 months). For patients with measurable and/or nonmeasurable baseline CNS disease, IRC CORR was 42.6% (95% CI, 34.2% to 51.4%), CDCR was 85.3% (95% CI, 78.2% to 90.8%), and median CDOR was 11.1 months (95% CI, 10.3 months to not evaluable). CORR was 35.8% (95% CI, 26.2% to 46.3%) for patients with prior radiotherapy (n = 95) and 58.5% (95% CI, 42.1% to 73.7%) for patients without prior radiotherapy (n = 41). As previously reported, alectinib was well tolerated, regardless of baseline CNS disease. Conclusion Alectinib showed good efficacy against CNS metastases, in addition to systemic activity, in crizotinib-refractory ALK-positive NSCLC.
引用
- Gadgeel SM, Shaw AT, Govindan R, et al. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2016. PMID: 27863201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。